pharmaphorum Podcast

pharmaphorum
  • 0.0（0則評分）
  • 生命科學
  • 隔週更新

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.

  1. 5 天前

    Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche

    Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche’s global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver disease epidemic that is being diagnosed too late and driving a growing health system crisis globally. The conversation also explores scalable diagnostic innovation and the role of this in addressing health system burden – metabolic liver disease projected to affect some 1.8 billion people by 2050, with global costs expected to exceed $2.3 trillion. You can listen to episode 271 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche

  2. 7月30日

    Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

    The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has put out new draft guidance codifying and, in some cases, modifying the fine print of the controversial law. They’ve also recently issued additional draft guidance on how they’ll handle the imminent introduction of Part B drugs into the programme. Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of the finer points of this latest communication from CMS – and to urge the industry to take advantage of the public comment periods associated with it. Curran and Comstock discuss small, but impactful, changes in CMS’s policies around deemed biologics, vaccines, and the special provisions that protect small biotechs. And Curran gives a rundown of what’s in – as well as what’s not in – the new MFP effectuation guidance, laying out how the differences in how Part D and Part B drugs are paid for leave some big question marks hanging over the programme. Tune in for an easy-to-understand deep dive into some complicated subject matter, and for a more comprehensive rundown don’t forget to check out Hogan Lovells’ policy briefs on the new draft rules and the MFP effectuation guidance.

    Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

  3. 7月21日

    CAMP4 on a new class of ASO in gene under expression

    SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms. In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases caused by gene under expression. Gold discusses the space and CAMP4’s CMP-002 study, targeting the regRNA associated SYNGAP1 gene. You can listen to episode 269 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    CAMP4 on a new class of ASO in gene under expression

  4. 7月14日

    BonelliErede on M&A in Europe: Andrea Carta Mantiglia

    The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US biotech M&A surge will indeed extend into Europe. The conversation touches upon the appetite for cross-border dealmaking, the growing role of private equity in European pharma and medtech, generational exits among family-owned pharma groups in Italy, and the role of digitalisation in all this. You can listen to episode 268 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    BonelliErede on M&A in Europe: Andrea Carta Mantiglia

  5. 7月7日

    Purespring on nephrology & gene therapy in kidney disease

    Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease. Indeed, Purespring’s lead programme is the podocyte-targeted gene therapy PS-002, which is for IgA nephropathy (or IgAN). The conversation also touches upon the evolution of the gene therapy landscape more generally, and where next with this type of innovation in the nephrology space. You can listen to episode 267 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    Purespring on nephrology & gene therapy in kidney disease

  6. 6月30日

    Parexel: Flawless execution, policy shifts & patient-centric design

    Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal. The conversation touches upon regulatory strategy and evolving policy shifts, trial design and execution – and the importance of patient centricity – as well as AI in drug development and medical leadership in drug development today. You can listen to episode 266 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    Parexel: Flawless execution, policy shifts & patient-centric design

  7. 6月23日

    Citius’ Leonard Mazur talks targeted immune therapy for CTCL

    Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL. Mazur discusses the landscape of unmet need in this space, as well as Citius’ advancement of clinical trials in other areas without approved treatments and the future horizon for such oncological innovations. You can listen to episode 265 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    Citius’ Leonard Mazur talks targeted immune therapy for CTCL

  8. 6月17日

    Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

    The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future radiopharmaceutical trends. Dr Cavey discusses the evolution of radiopharma, beyond the original “two pillars” of GEP-NETs and PSMA, including the move towards a multi-isotope model, as well as ITM’s pipeline and the potential growth of the broader radiopharma ecosystem going forward. You can listen to episode 263 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

    Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey
顯示全部 (351)

簡介

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.

資訊

  • 創作者
    pharmaphorum
  • 活躍年代
    2018年 - 2026年
  • 集數
    351
  • 年齡分級
    兒少適宜
  • 版權
    © 2022 Pharmaphorum
  • 節目網站
    pharmaphorum Podcast

你可能也會喜歡